The rationale for radical cystectomy as primary therapy for T4 bladder cancer.

Perioperative morbidity of radical cystectomy: A review. Indian J Urol (2011) 0.84

Efficacy of robot-assisted radical cystectomy (RARC) in advanced bladder cancer: results from the International Radical Cystectomy Consortium (IRCC). BJU Int (2014) 0.79

Laparoscopic radical cystectomy: initial experience using the single-incision triangulated umbilical surgery (SITUS) technique. World J Urol (2012) 0.78

A pure microcytic bladder carcinoma synchronous to prostatic adenocarcinoma. Rare Tumors (2011) 0.75

Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery. Transl Androl Urol (2016) 0.75

Intraoperative frozen section evaluation of ureteral and urethral margins: studies of 203 consecutive radical cystoprostatectomy for men with bladder urothelial carcinoma. Am J Clin Exp Urol (2014) 0.75

Clinicopathologic characteristics and overall survival in patients with bladder cancer involving the gastrointestinal tract. Virchows Arch (2013) 0.75

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35

Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol (2002) 3.49

The role of percutaneous nephrostomy in malignant ureteric obstruction. Ann R Coll Surg Engl (2005) 1.30

Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. J Urol (2001) 1.13

Radical cystectomy for elderly patients with bladder carcinoma: an updated experience with 404 patients. Cancer (1998) 1.08

Radical cystectomy in patients aged > or = 75 years: an updated review of patients treated with curative and palliative intent. BJU Int (2005) 0.94

Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer. Int J Radiat Oncol Biol Phys (2003) 0.91

Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. Int J Radiat Oncol Biol Phys (2000) 0.89

Four years experience in bladder preserving management for muscle invasive bladder cancer. Eur Urol (2005) 0.87

Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. Urology (2004) 0.84

Evaluation for surrogacy of end points by using data from observational studies: tumor downstaging for evaluating neoadjuvant chemotherapy in invasive bladder cancer. Clin Cancer Res (2006) 0.83

Organ-sparing treatment in muscle-invasive bladder cancer. Strahlenther Onkol (2005) 0.82

The efficacy of neoadjuvant chemotherapy in invasive bladder cancer. Int Urol Nephrol (2002) 0.81

Symptomatic relief of patients with advanced bladder carcinoma after regional intra-arterial chemotherapy. Anticancer Res (2004) 0.81

Conservative surgery, patient selection, and chemoradiation as organ-preserving treatment for muscle-invading bladder cancer. Semin Oncol (1996) 0.80

25-year experience in the management of invasive bladder cancer by radical cystectomy. Eur Urol (1998) 0.79

Complications and results after cystectomy in male and female patients with locally invasive bladder cancer. Eur Urol (1998) 0.79

Radical cystectomy versus alternative treatments for muscle-confined bladder cancer. Int Urol Nephrol (2001) 0.79

Salvage cystectomy after failure of interstitial radiotherapy and external beam radiotherapy for bladder cancer. BJU Int (2004) 0.78

EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol (2010) 8.21

Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol (2011) 5.59

Retracted Generation of pluripotent stem cells from adult human testis. Nature (2008) 5.49

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44

Renal cell carcinoma guideline. Eur Urol (2007) 3.42

Adjuvant radiotherapy for patients with locally advanced prostate cancer--a new standard? Eur Urol (2008) 3.27

The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol (2009) 2.92

In vitro investigations of tissue-engineered multilayered urothelium established from bladder washings. Eur Urol (2008) 2.84

Urinary diversion. Urology (2007) 2.65

OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol (2013) 2.59

Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol (2008) 2.48

Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45

The periprostatic autonomic nerves--bundle or layer? Eur Urol (2008) 2.38

Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol (2012) 2.29

ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol (2012) 2.19

Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy. BJU Int (2012) 1.99

Moderate degradation does not preclude microarray analysis of small amounts of RNA. Biotechniques (2003) 1.95

Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann Neurol (2010) 1.84

Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol (2012) 1.81

Minimally invasive percutaneous nephrolithotomy: an alternative to retrograde intrarenal surgery and shockwave lithotripsy. World J Urol (2012) 1.72

HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol (2009) 1.72

Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. J Urol (2008) 1.68

Totally intracorporeal replacement of the ureter using whole-mount ileum. J Endourol (2014) 1.67

Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol (2012) 1.63

Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors. Urology (2009) 1.59

The commonly performed nerve sparing total prostatectomy does not acknowledge the actual nerve courses. J Urol (2009) 1.51

Y pouch neobladder-a simplified method of intracorporeal neobladder after robotic cystectomy. J Endourol (2014) 1.51

MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol (2006) 1.50

Urethral ultrasound as a screening tool for stricture recurrence after oral mucosa graft urethroplasty. Urology (2011) 1.50

Point-of-Care Tests for Bladder Cancer: The Influencing Role of Hematuria. Adv Urol (2011) 1.49

Influence of urinary tract instrumentation and inflammation on the performance of urine markers for the detection of bladder cancer. Urology (2012) 1.47

Quantification of tumor cell burden by analysis of single cell lymph node disaggregates in metastatic prostate cancer. Prostate (2010) 1.45

Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int (2014) 1.43

Radical cystectomy and orthotopic bladder replacement in females. Eur Urol (2006) 1.42

Dorsal onlay skin graft urethroplasty in patients older than 65 years. Urology (2010) 1.41

Current evidence of transurethral Ho:YAG and Tm:YAG treatment of bladder cancer: update 2014. World J Urol (2014) 1.41

Immunoreactivity of p63 in monolayered and in vitro stratified human urothelial cell cultures compared with native urothelial tissue. Eur Urol (2007) 1.41

Prolonged percutaneous SNM testing does not cause infection-related explanation. BJU Int (2012) 1.41

Tissue engineering for the lower urinary tract: a review of a state of the art approach. Eur Urol (2007) 1.41

No androgen withdrawal syndrome for enzalutamide: a report of disease dynamics in the postchemotherapy setting. Eur Urol (2013) 1.40

Sexual dysfunction is common and overlooked in female patients with hypertension. J Sex Marital Ther (2002) 1.40

Steerable antegrade stenting: a new trick of the trade. Int Braz J Urol (2007) 1.39

Urinary calculi composed of uric acid, cystine, and mineral salts: differentiation with dual-energy CT at a radiation dose comparable to that of intravenous pyelography. Radiology (2010) 1.39

Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol (2013) 1.38

Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol (2011) 1.36

Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int (2008) 1.32

Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol (2009) 1.32

Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther (2010) 1.32

Expansion and differentiation of neural progenitors derived from the human adult enteric nervous system. Gastroenterology (2009) 1.32

Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. BJU Int (2014) 1.31

EAU guidelines on laser technologies. Eur Urol (2012) 1.27

Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol Cell Proteomics (2006) 1.26

Is there a need to further subclassify pT2 renal cell cancers as implemented by the revised 7th TNM version? Eur Urol (2010) 1.26

Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol (2013) 1.25

Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol (2012) 1.25

Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol (2011) 1.21

Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate (2009) 1.20

Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int (2011) 1.20

Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res (2009) 1.19

Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer (2010) 1.18

Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur Urol (2013) 1.18

Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol (2008) 1.16

Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer. BMC Cancer (2010) 1.14